SolasCure enrols first patient in a next Phase II clinical trial to advance Aurase Wound Gel
Phase II clinical trial to determine the efficacy of Aurase Wound Gel at a higher concentration of the active enzyme Tarumase in venous leg ulcers
District Council encourages parents to claim free Healthy Start vouchers
Parents of children under the age of four years old are being encouraged to check if they are eligible for free Healthy Start vouchers to help buy food and milk.
New research - Weight loss increases risk of death for obese adults
Study finds significant weight loss raises risk for those with cardiovascular disease.
Unlocking the mysteries of the brain: highlights from the Cambridge Festival
As discussions around mental health and cognitive wellbeing continue to dominate headlines, the Cambridge Festival (19 March - 4 April 2025) offers a timely, in-depth exploration of the brain’s complexities.
CUH appoints a new Non-Executive Director
Mr John Crompton has been appointed as a Non-Executive Director of Cambridge University Hospitals NHS Foundation Trust (CUH), which runs Addenbrooke’s and The Rosie hospitals.
Cellular changes as lung damage worsens in COVID-19 revealed
Changes in the cellular response during lung damage caused by SARS-CoV-2 – the virus behind COVID-19 – have been uncovered. Researchers reveal distinct phases where waves of immune responses give way to lung fibrosis – scarring of the lungs – in severe COVID-19.
Young Carers Action Day – Education Summit 2025
On 12 March 2025, the Young Carers in Education Summit brought together educators, charities and most importantly, young carers from across the region for a day of sharing, learning, and empowerment.
Bio-Rad launches XP-Design Assay Salmonella Serotyping Solution for rapid and accurate food safety testing
HERCULES, Calif. — 10 March Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, announces the launch of XP-Design Assay Salmonella Serotyping Solution designed for the rapid detection and precise characterization of
WaveFX revolutionises webcasting & event production with a 5-star approach
Let’s be honest, most webcasts are either too complicated, too boring, or both. That’s where WaveFX comes in. They believe event production should be stress-free, engaging, and actually fun (yes, even for corporate events!). Whether it’s a hybrid conference, awards show, product launch, or live stream, we bring a fresh, people-first approach that keeps audiences watching.
Arecor establishes partnership with biopharmaceutical company to develop novel formulation of peptide therapy
Partner to fund development work with option to acquire rights to proprietary formulation under Arecor’s technology licensing model.
H.E.L Group signs research agreement with the Institute of Chemical Technology (ICT) in Mumbai
Collaboration with ICT Mumbai will focus on advancing process safety and chemical synthesis in India
Shift Bioscience announces key appointments to advance rejuvenation therapeutics pipeline
Jill Reckless (CEO, RxCelerate) appointed as Translation Advisor Laurence Reid joins as Non-Executive Director, previously Decibel Therapeutics, Warp Drive Bio, Alnylam, and Millennium PharmaceuticalsCambridge, UK, 12 March 2025:&
Gyles Brandreth urges public to Support CBM UK’s World in Focus Campaign to end avoidable sight loss
Broadcaster and writer Gyles Brandreth is lending his passionate support to Cambridge based, Global Disability Inclusion charity, CBM UK’s World in Focus campaign, highlighting the urgent need to tackle avoidable sight loss affecting 1.1 billion people worldwide.
Two Milner Institute bio-incubator companies win cofinitive #21toWatch awards
Two companies based at the Milner Therapeutics Institute bio-incubator have won Cofinitive #21toWatch awards.
Trainee surgeon scoops coveted award
An Addenbrooke’s doctor who is in the final stages of training to become a vascular surgeon has been given a prestigious award for her research.
Highlights from another great year for Cambridge Enterprise
The Cambridge Enterprise Annual Review 2024 showcases how the commercialisation of groundbreaking research creates tangible societal benefits.
Biotech dominates at 2025 #21toWatch Awards with winners focused on remedying persisting medical challenges
The #21toWatch Top21.2025 winners have been announced at an inspirational awards ceremony at The Glasshouse innovation hub in Cambridge.
25 years of Guardtech: the past, present and future as told by their founder
The Suffolk contamination control specialists constructed their first ever cleanroom 25 years ago – Director and founder Ray Wheeler explains how we became the business we are today
Five Alarm Bio and Proteotype collaborate on new anti-aging approach
Five Alarm Bio Ltd and Proteotype Diagnostics Ltd have been awarded a highly-competitive collaborative grant from the Babraham Research Campus from the Campus Innovation Award programme, to develop and test novel biomarkers for cellular senescence.
Wilson Connectivity: Expanding the reach of wireless solutions with private 5G and enterprise-grade coverage
Connectivity really embodies what we’re about and we’re about connecting everyone, everywhere.” says Bruce Lancaster, CEO of Wilson Connectivity.
From Wilson Electronics to Wilson Connectivity: A Broader Vision
New insights into ageing revealed
The way in which blood stem cells evolve over a lifespan differs greatly between humans and mice, new research reveals. The findings provide a new understanding of the critical factors that influence tissue ageing.
Breathing easier: tackling Alzheimer's through respiratory insights
At electronRx, we are constantly looking for ways we can leverage cutting-edge technology to redefine healthcare. We are excited about the potential of our work in pulmonary function and its connection to neurodegenerative diseases like Alzheimer's.
OBN invites life science R&D companies, industry leaders, academics, and investors to BioTrinity 2025
Opening keynote from Tim Haines, Executive Partner at Abingworth, to provide a review of the life science investment landscapeExpected to welcome c900 delegates [SB1] spanning early-stage life science R&D,
TRIMTECH Therapeutics raises $31M seed funding to advance targeted protein degradation pipeline for treatment of neurodegenerative diseases
Oversubscribed financing led by Cambridge Innovation Capital and SV Health Investors’ Dementia Discovery Fund with M Ventures and Pfizer Ventures joining Investment will support further development of CNS penetrant therapeutics based on the Company’s TRIMTACTM
Mestag Therapeutics appoints Dr. Matthew Sleeman as Chief Scientific Officer
Mestag Therapeutics, a biotech company harnessing fibroblast immunology for the benefit of patients with inflammatory disease and cancer, announces that Matthew Sleeman, PhD, has been appointed Chief Scientific Officer.